Biology of obsessive–compulsive disorder

TSC Alliance Applauds Release of Updated International Guidelines for Tuberous Sclerosis Complex Diagnostic and Management Recommendations

Retrieved on: 
Tuesday, August 3, 2021
Rare diseases, Autosomal dominant disorders, Autism, Biology of obsessive–compulsive disorder, Intellectual disability, Tuberous sclerosis, Abnormal psychology, Clinical medicine, Branches of biology, TSC, TSC1

SILVER SPRING, Md., Aug. 3, 2021 /PRNewswire/ --Today, the TSC Alliance announced the publication of two new papers in the prestigious Pediatric Neurology: " Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations " and " Beyond the Guidelines: How We Can Improve Healthcare for People with Tuberous Sclerosis Complex Around the World ."

Key Points: 
  • SILVER SPRING, Md., Aug. 3, 2021 /PRNewswire/ --Today, the TSC Alliance announced the publication of two new papers in the prestigious Pediatric Neurology: " Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations " and " Beyond the Guidelines: How We Can Improve Healthcare for People with Tuberous Sclerosis Complex Around the World ."
  • Tuberous sclerosis complex (TSC) causes tumors to grow in different organs and can impair their function, primarily the brain, heart, kidneys, skin and lungs.
  • "The TSC Alliance is thrilled to announce updated 'gold standards' for TSC diagnosis, surveillance and management," said President & CEO Kari Luther Rosbeck.
  • Additionally, TSC International , a consortium of organizations that support individuals with TSC around the world, penned the companion piece, "Beyond the Guidelines: How We Can Improve Healthcare for People with Tuberous Sclerosis Complex from Around the World."

Toxoplasmosis Treatment Drugs Market Report - Global Size, Share, Outlook, and Opportunity Analysis, 2016-2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 27, 2021
General Health, Pharmaceutical, Health, Clinical medicine, Medicine, Conoidasida, Health, Biology of bipolar disorder, Biology of obsessive–compulsive disorder, Toxoplasmosis, Zoonoses, Toxoplasma gondii, Chemotherapy

The "Toxoplasmosis Treatment Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Toxoplasmosis Treatment Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Rising number of chemotherapy procedures can lead to increase in the number of toxoplasmosis infection thereby assisting the market growth.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
    The global toxoplasmosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
    Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global toxoplasmosis treatment drugs market.
  • Global Toxoplasmosis Treatment Drugs Market, By Indication:
    Global Toxoplasmosis Treatment Drugs Market, By Route of Administration:
    Global Toxoplasmosis Treatment Drugs Market, By Drug Class:

Saniona Hosts Research and Development (R&D) Day on Proprietary Ion Channel Drug Discovery Engine and Pipeline Programs

Retrieved on: 
Thursday, May 20, 2021
Branches of biology, Neurochemistry, GABAA receptor positive allosteric modulators, Biology of obsessive–compulsive disorder, gamma-Aminobutyric acid, Neurotransmitters, Neuroscience

b'Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it hosted a virtual R&D day event, during which it discussed its ion channel drug discovery engine and proprietary IONBASE\xe2\x84\xa2 database.

Key Points: 
  • b'Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it hosted a virtual R&D day event, during which it discussed its ion channel drug discovery engine and proprietary IONBASE\xe2\x84\xa2 database.
  • The core of this engine is Saniona\xe2\x80\x99s proprietary IONBASE database, which contains structure-activity data for more than 120,000 compounds.
  • Of these, 20,000 are Saniona\xe2\x80\x99s proprietary compounds, generated over 20 years and enriched for optimal ion channel modulation.\nSAN711 is a first-in-class drug candidate that selectively enhances the effects of GABA-A on \xce\xb13 containing receptors.
  • Saniona\xe2\x80\x99s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated.

Tuberous Sclerosis Alliance Evolves to TSC Alliance and Unveils New Brand

Retrieved on: 
Monday, May 17, 2021
Rare diseases, Autism, Biology of obsessive–compulsive disorder, Intellectual disability, Tuberous sclerosis, TSC, Abnormal psychology, Branches of biology, Clinical medicine

b'Today, the Tuberous Sclerosis Alliance formally unveiled a new brand and new name: TSC Alliance .

Key Points: 
  • b'Today, the Tuberous Sclerosis Alliance formally unveiled a new brand and new name: TSC Alliance .
  • Nearly one million people worldwide have TSC.\nIn 1974, four mothers of children with TSC founded the organization, originally known as the National Tuberous Sclerosis Association.
  • In 2000, the name changed to Tuberous Sclerosis Alliance to reflect the organization\'s growth and commitment to the importance of partnerships.
  • "\nThe TSC Alliance is an internationally recognized nonprofit dedicated to finding a cure for tuberous sclerosis complex while improving the lives of those affected.

Nutrition21 Launches Newest Ingredient -- Lustriva™ -- Into the Fast-Growing Beauty-From-Within Market

Retrieved on: 
Monday, March 1, 2021
Chemistry, Physical sciences, Natural sciences, Biology of bipolar disorder, Biology of obsessive–compulsive disorder, Inositol, Biotin, Boron

1, 2021 /PRNewswire/ --Nutrition21, LLC ("Nutrition21") has announced the launch of its latest ingredient, Lustriva, a clinically tested beauty-from-within ingredient that contains Bonded Arginine Silicate (arginine silicon inositol complex) and Magnesium Biotinate (Nutrition21's proprietary biotin formulation).

Key Points: 
  • 1, 2021 /PRNewswire/ --Nutrition21, LLC ("Nutrition21") has announced the launch of its latest ingredient, Lustriva, a clinically tested beauty-from-within ingredient that contains Bonded Arginine Silicate (arginine silicon inositol complex) and Magnesium Biotinate (Nutrition21's proprietary biotin formulation).
  • Studies have also demonstrated that Lustriva can enhance hair growth and density and improve skin elasticity and overall appearance.
  • James Komorowski, MS, CNS, Chief Science Officer of Nutrition21, commented, "This is an exciting launch for Nutrition21, and we are proud to bring this clinically tested, patent-protected ingredient to the beauty market.
  • Science is the biggest differentiator for Lustriva and gives us confidence that the market and consumers will embrace it.

Nutrition21's nooLVL® Earns Top Spot in Player1 Launch

Retrieved on: 
Wednesday, January 27, 2021
Branches of biology, Hormones, Medical specialties, Biology of bipolar disorder, Biology of obsessive–compulsive disorder, Inositol, Insulin, Arginine

For its new line, Rule One Proteins sought out nooLVL for its cognitive benefits, specifically reaction time, accuracy, alertness, visual attention, and focus.

Key Points: 
  • For its new line, Rule One Proteins sought out nooLVL for its cognitive benefits, specifically reaction time, accuracy, alertness, visual attention, and focus.
  • Billed as a "Gaming Performance Booster", Player1 is available in Rainbow Respawn and Gummy Grenade varieties.
  • nooLVL is comprised of two components: Bonded Arginine Silicate combined with an additional dose of inositol.
  • Most recently, nooLVL was the subject of a clinical study published in Nutrients , which compared it to placebo following acute ingestion by gamers.

Tuberous Sclerosis Alliance Announces Director, Medical Affairs

Retrieved on: 
Tuesday, November 17, 2020
Rare diseases, Autosomal dominant disorders, Autism, Biology of obsessive–compulsive disorder, Intellectual disability, Tuberous sclerosis, Abnormal psychology, Health, Branches of biology

SILVER SPRING, Md., Nov. 17, 2020 /PRNewswire/ -- Today the Tuberous Sclerosis Alliance (TS Alliance) announced Ashley Pounders, MSN, FNP-C, will join the organization December 1 as its first Director, Medical Affairs.

Key Points: 
  • SILVER SPRING, Md., Nov. 17, 2020 /PRNewswire/ -- Today the Tuberous Sclerosis Alliance (TS Alliance) announced Ashley Pounders, MSN, FNP-C, will join the organization December 1 as its first Director, Medical Affairs.
  • In this new position, Pounders will provide information and assistance to constituents needing help accessing clinical care and FDA-approved treatments for tuberous sclerosis complex (TSC).
  • "The TS Alliance is thrilled to add Ashley to our team," said Kari Luther Rosbeck, TS Alliance President & CEO.
  • "As the new Director of Medical Affairs, I am delighted to use my skills to lead initiatives to advance medical treatments and clinical research, provide quality education for clinical staff and bridge the gap of medical disparities by eliminating barriers inhibiting access to quality care."

Jay Mohr to Headline 19th Annual Comedy for a Cure® Fall Virtual Edition

Retrieved on: 
Thursday, October 8, 2020
Comedians, Entertainers, Health, Biology of obsessive–compulsive disorder, Intellectual disability, Tuberous sclerosis, Mohr, Ben Gleib, Kira Soltanovich, Sclerosis, Autism, Kira

HOLLYWOOD, Calif., Oct. 8, 2020 /PRNewswire/ --Today, the Tuberous Sclerosis Alliance (TS Alliance) announced Jay Mohr, comedian, actor and best-selling author, will headline its 19th Annual Comedy for a Cure Fall Virtual Edition on Sunday, October 18 at 5 pm Pacific Time.

Key Points: 
  • HOLLYWOOD, Calif., Oct. 8, 2020 /PRNewswire/ --Today, the Tuberous Sclerosis Alliance (TS Alliance) announced Jay Mohr, comedian, actor and best-selling author, will headline its 19th Annual Comedy for a Cure Fall Virtual Edition on Sunday, October 18 at 5 pm Pacific Time.
  • TSC causes tumors to form in vital organs and is the leading genetic cause of both autism and epilepsy.
  • This year's lineup includes headliner Jay Mohr with additional performances by Kira Soltanovich , Ben Gleib and Adam Ray .
  • Mohr, who has been performing since he was 16 years old, is a comedian, actor and best-selling author.

Tuberous Sclerosis Alliance and Seizure Tracker™ Partner to Promote Data Sharing and Biosample Collection

Retrieved on: 
Friday, June 19, 2020
Medicine, Health, Clinical medicine, Rare diseases, Autism, Biology of obsessive–compulsive disorder, Intellectual disability, Tuberous sclerosis, Epileptic seizure, Sclerosis, TSC

SILVER SPRING, Md., June 19, 2020 /PRNewswire/ --Today the Tuberous Sclerosis Alliance (TS Alliance) and Seizure Tracker announced a partnership to promote data sharing and biosample collection from people with tuberous sclerosis complex (TSC), a rare genetic condition that causes tumors to form in vital organs.

Key Points: 
  • SILVER SPRING, Md., June 19, 2020 /PRNewswire/ --Today the Tuberous Sclerosis Alliance (TS Alliance) and Seizure Tracker announced a partnership to promote data sharing and biosample collection from people with tuberous sclerosis complex (TSC), a rare genetic condition that causes tumors to form in vital organs.
  • The Data Share system is designed to enable website and mobile diary users to link their personally reported data to partner organizations' managed databases.
  • "Combining the TS Alliance's Natural History Database and seizure outcome data from Seizure Tracker has the potential to change the way we think about and treat seizures in people living with tuberous sclerosis complex," says Robert Moss, Co-Founder and President of Seizure Tracker.
  • Reports generated on the Seizure Tracker system provide extensive data visualizations comparing therapies against seizure activity changes while highlighting trends.

Tuberous Sclerosis Complex: 2020 Pipeline Insights - Therapeutics, Products, Companies and More - ResearchAndMarkets.com

Retrieved on: 
Monday, April 20, 2020
Pharmaceutical, Health, Other Health, Rare diseases, Abnormal psychology, Autism, Biology of obsessive–compulsive disorder, Intellectual disability, Tuberous sclerosis, Health, Behavioural sciences

Tuberous Sclerosis Complex Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Tuberous Sclerosis Complex market.

Key Points: 
  • Tuberous Sclerosis Complex Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Tuberous Sclerosis Complex market.
  • A detailed picture of the Tuberous Sclerosis Complex pipeline landscape is provided, which includes the disease overview and Tuberous Sclerosis Complex treatment guidelines.
  • The assessment part of the report embraces in-depth Tuberous Sclerosis Complex commercial assessment and clinical assessment of the Tuberous Sclerosis Complex pipeline products from the pre-clinical developmental phase to the marketed phase.
  • How many Tuberous Sclerosis Complex emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Tuberous Sclerosis Complex?